psilocybin; depression; terminal cancer; CME; CNE: psilocybin; depression; terminal cancer; CME; CNEPsilocybin is a naturally occurring alkaloid found in more than 200 species of mushrooms. This compound, which was first isolated by the Swiss chemist Albert Hofman in 1959, is the active constituent of psychedelic mushrooms which are thought to have been util...
Objective: The purpose of the present study was to obtain patient information across a wide geography about medical history, drug use, symptoms, and treatments of individuals diagnosed with hallucinogen persisting perception disorder (HPPD). Methods: The study was an internet survey that yielded 26 HPPD patients from North America (81%), Europe (12%), and So...
The use of classical psychedelics in a therapy setting can have a positive impact on many different psychiatric disorders such as mood disorders, anxiety, addiction, and overall spiritual wellbeing (Carhart-Harris et al., 2017). However, medicinal psychedelics have been stigmatized and removed as an option of treatment, just as medical cannabis once was. If ...
Back to table of contents Previous article Next article Clinical and Research NewsFull AccessIs Psychedelic Medicine on the Horizon?Nick ZagorskiNick ZagorskiPublished Online:28 Feb 2019https://doi.org/10.1176/appi.pn.2019.1b1AbstractNew research suggests that, if used properly, psychedelic compounds may be able to help patients with treatment-resistant psyc...
IntroductionMood, anxiety, and substance-use disorders are among the most prevalent psychiatric disorders in the population. Although several pharmacological treatments are available, they are not effective for a significant proportion of patients and are associated with several adverse reactions. Therefore, new treatments should be explored. Recent studies ...
Mental disorders are rising while development of novel psychiatric medications is declining. This stall in innovation has also been linked with intense debates on the current diagnostics and explanations for mental disorders, together constituting a paradigmatic crisis. A radical innovation is psychedelic-assisted psychotherapy (PAP): professionally supervis...
BackgroundNatural speech analytics has seen some improvements over recent years, and this has opened a window for objective and quantitative diagnosis in psychiatry. Here, we used a machine learning algorithm applied to natural speech to ask whether language properties measured before psilocybin for treatment-resistant can predict for which patients it will ...
RationaleRecent studies have supported the safety and efficacy of psychedelic therapy for mood disorders and addiction. Music is considered an important component in the treatment model, but little empirical research has been done to examine the magnitude and nature of its therapeutic role.ObjectivesThe present study assessed the influence of music on the ac...
BackgroundPsychiatric research in the 1950s and 1960s showed potential for psychedelic medications to markedly alleviate depression and suffering associated with terminal illness. More recent published studies have demonstrated the safety and efficacy of psilocybin, MDMA, and ketamine when administered in a medically supervised and monitored approach. A sing...
Recent, well-controlled - albeit small-scale - clinical trials show that serotonergic psychedelics, including psilocybin and lysergic acid diethylamide, possess great promise for treating psychiatric disorders, including treatment-resistant depression. Additionally, fresh results from a deluge of clinical neuroimaging studies are unveiling the dynamic effect...
BackgroundTreatment resistant cluster headache and migraine patients are exploring alternative treatments online. The aim of this study was to improve comprehension regarding the use of non-established or alternative pharmacological treatments used by sufferers of cluster headaches and migraines.MethodsA qualitative thematic analysis of the users' own accoun...
Psilocybin and other 5-hydroxytryptamine2A agonist classic psychedelics have been used for centuries as sacraments within indigenous cultures. In the mid-twentieth century they were a focus within psychiatry as both probes of brain function and experimental therapeutics. By the late 1960s and early 1970s these scientific inquires fell out of favor because cl...
Background Recently, scientific interest in the therapeutic potential of serotonergic and psilocybin hallucinogens (psychedelics) such as lysergic acid diethylamide (LSD) and entactogens like 3,4-methylendioxymethamphetamine (MDMA) within the framework of psychotherapy has resumed. The present article provides an overview on the current evidence on substance...
Psilocybin, a psychoactive component of magic mushrooms, is thought to have therapeutic potential in psychiatric disorders but its mechanism of action within the brain is unclear. In a study, researchers gave two doses of psilocybin to 19 patients with treatment-resistant depression, and studied blood flow within the brain using functional magnetic resonance...
In medicine we must always expect the unexpected. Medicine is replete with paradoxes, where poisons become cures. Snake venom is deadly but is being used to treat some cancers, (1) because it produces contortrostatin, a protein that paralyzes cancer cells and prevents them from migrating. Venoms from spiders are being investigated as a treatment to slow the ...
Unipolar mood disorders, including major depressive disorder and persistent depressive disorder (dysthymia), confer high rates of disability and mortality and a very high socioeconomic burden. Current treatment is suboptimal in most cases and there is little of note in the pharmaceutical development pipeline. The psychedelic drugs, including lysergic acid di...
To date, pharmacological treatments for mood and anxiety disorders and for drug dependence show limited efficacy, leaving a large number of patients suffering severe and persistent symptoms. Preliminary studies in animals and humans suggest that ayahuasca, psilocybin and lysergic acid diethylamide (LSD) may have antidepressive, anxiolytic, and antiaddictive ...
